Entegrion Licenses Stasilon Bleeding Control Dressing to Beeken BioMedical

Research Triangle Park, NC-based life sciences development company focused on expanding the therapeutic potential of the human vascular system signs agreement with new Chicago-based medical device company to continue development and commercialization of FDA-cleared hemostatic dressing.
Research Triangle Park, NC (PRWEB) April 20, 2011
Entegrion, the life sciences development company focused on expanding the therapeutic potential of the human vascular system, announces it has licensed Stasilon® to the Chicago-based medical device company Beeken BioMedical. Stasilon® is an FDA-cleared, single-use hemostatic dressing applied externally with mechanical compression to temporarily control bleeding in lacerations, punctures, abrasions and incisions.
“Beeken BioMedical is committed to continue the development and commercialization of Stasilon®,” said Richard A. Kendall, President and CEO of newly formed Beeken BioMedical. “This novel medical device that extends across all of healthcare gives our company an immediate presence in the healthcare industry with opportunities to expand our sales and distribution model.”
“We selected Stasilon® as the company's initial investment for many reasons, including technology innovation and the fact that it is a low cost but effective alternative to current hemostatic devices in the market and a strategic fit to our global distribution model,” said Peter Beemsterboer, Chairman of Beeken BioMedical. “We look forward to having Entegrion as a strategic partner to further develop our product portfolio.”
Entegrion, which developed the hemostatic woven dressing in collaboration with researchers at the University of North Carolina, commented on the agreement. “We are pleased to partner with Beeken BioMedical in the introduction of Stasilon® to the surgical and wound care community. We are confident they have the experience, drive and imagination to successfully represent the technology, and, as importantly, identify additional unmet medical needs that can be addressed by future generations of products,” said Joseph DaCorta, Entegrion's Vice President and Chief Technology Officer. “They are the ideal partners for us.”
Beemsterboer and Kendall are the co-founders of Beeken BioMedical. The entrepreneurs have diverse and extensive backgrounds in developing multi-million-dollar businesses that introduce new technologies and services into healthcare and non-healthcare-related industries. The company has selected an experienced management team to continue the development and growth of the company.
Regulated as a medical device, Stasilon® addresses the immediate need to control bleeding surfaces by treating wounds caused by trauma with a novel dual-fiber hemostatic dressing. Beeken BioMedical will focus on the unique features of Stasilon® to continue to be among the first choice of hemostasis devices selected in surgery, wound care, emergency medicine, industrial and consumer care. Potential market opportunities range from hospitals, clinics, physician offices, long term and emergency care facilities, municipalities, veterinary clinics, and athletics to over-the-counter use by consumers

U.S. Navy Awards Entegrion Contracts for $4 Million

August 6, 2009 -- The U.S. Navy has awarded two additional contracts to the life sciences company Entegrion, Inc., for implementation of the company's proprietary technologies to improve the safety and availability of blood-derived products for treating combat injuries. Recent medical research has demonstrated that such blood component therapy is essential in responding to traumatic injury, especially on the battlefield. The base contracts total about $4 million, with an additional $2 million for expanded research.

"Our military does a heroic job in overcoming the logistical challenges of ensuring that critically needed blood supplies are available when and where they are needed," said Joseph DaCorta, Entegrion's Chief Technology Officer. "Trends in clinical practice are moving toward earlier and more aggressive use of blood components after serious injury. However, availability of such therapies is often seriously restricted by shelf-life limitations and storage requirements. Technologies like ours to produce blood-derived products that can be stored for longer periods, do not require refrigeration, and have fewer pathogens will support both military and civilian medical operations by ensuring both the safety and timely availability of blood products to treat serious injuries, particularly in remote and austere areas."

The first of the new contracts is for advanced development of Entegrion's Stasix®, a dehydrated platelet-derived hemostatic agent that can be reconstituted and transfused when needed for the control of non-compressible internal bleeding. The second contract is for advanced development of Entegrion's product, Resusix®, a dehydrated, pathogen-reduced, fresh human plasma for infusion in trauma patients to expand blood volume, correct abnormal coagulation function, and support hemostasis.

"We are honored to have been chosen by the Navy to assist them in meeting these critical requirements. For Entegrion, this represents the fourth major contract for such work over the last six years. We remain totally committed to building on our track record of providing timely and effective R&D to deliver these much needed therapeutics to both our military and the civilian markets that will follow," said Stan Eskridge, Chief Executive Officer of Entegrion.

Entegrion

Just received this video to share with you of Entegrion created Stasilon and its mode of action.

Entegrion achieve FDA approval

Entegrion, Inc., a privately owned life sciences product development company specializing in technologies for hemorrhage control, resuscitation, and tissue repair, announced that it has received 510(k) market approval from the U. S. Food and Drug Administration (FDA) for its hemostatic medical textile technology. The first application of the technology is Stasilon FR – hemostatic wound dressings for first responders. This market includes EMS workers, police officers, emergency personnel and fire fighters. The Stasilon FR – hemostatic wound dressing was approved by the FDA for use by medical professionals under prescription and “over-the-counter” by consumers to control bleeding resulting from “minor cuts and abrasions” as well as “lacerations, punctures and incisions.” Pending acceptance of an amendment to the FDA approval, a second version of the technology will be implemented as Stasilon OR – hemostatic surgical pads.
Entegrion 510K available HERE

Blood-staunching bandages

Conventional gauze bandages do not work well enough because, although they absorb blood, they do not prevent its flow. Thomas Fischer and colleagues at the Francis Owen Blood Research Laboratory at the University of North Carolina at Chapel Hill think they may have the solution.
His team has discovered that bandages made from about 65% glass fibre and 35% bamboo fibre not only absorb blood but also stimulate the body's ability to staunch the flow by triggering the release of blood-clotting factors such as thrombin or fibrinogen. They say the bandages work even better if they are themselves impregnated with blood-clotting factors.
Given the number of military casualties in Afghanistan and Iraq this is an idea that could well be fast-tracked. The idea is part-owned by a company called Entegrion, which was co-founded by Fischer. So all the pieces are in place for the bandages to be commercialised soon.
Read the full patent application for blood-staunching bandages.